cbdMD, Inc announced a private placement and entered into securities purchase agreement with Institutional investors pursuant to which it issued an aggregate of 1,000,000 shares of Series C Convertible Preferred Stock at a price of $2.25 per share for aggregate gross proceeds of $2,250,000 on December 19, 2025. The Series C shares have a 10% annual dividend and are convertible at the option of the holder into the Company's common stock at an initial conversion price of $2.25 per share.
cbdMD, Inc. is a cannabidiol (CBD) company. The Company has a comprehensive line of United States produced, THC-free CBD products, including NSF Certified for Sport products, as well as its new Full Spectrum products. The Company's flagship brands include cbdMD and Paw CBD, as well as its functional mushroom brand ATRx Labs. Its cbdMD brand includes high-grade, premium CBD products including CBD tinctures, CBD gummies, CBD topicals, CBD capsules, CBD sleep aids and CBD drink products including its Herbal Oasis Social Tonic and an array of Farm Act compliant Delta 9 products. Its Paw CBD brand of pet products includes veterinarian-formulated products including tinctures, chews, topicals products in varying strengths, and its ATRx brand of natural functional mushroom support. Its cbdMD, Paw CBD and ATRx products are distributed through its e-commerce websites, third party e-commerce sites, select distributors and marketing partners as well as a variety of brick-and-mortar retailers.
